This inventor holds 5 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Cebina Gmbh, Universitat Wien, University of Vienna. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2021-2026
Title: The Innovative Contributions of Robert Konrat
Introduction
Robert Konrat is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of antiviral treatments, particularly in the fight against coronavirus. With a total of 5 patents to his name, Konrat's work is paving the way for new therapeutic methods.
Latest Patents
Konrat's latest patents focus on antiviral treatments utilizing Azelastine compounds. One of his patents describes a method of treating subjects in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment that includes an antiviral effective amount of an Azelastine compound. The specified dosage ranges from 0.1 to 500 µg per dose. Additionally, he has developed methods for using Azelastine compounds as antiviral substances in medicinal products aimed at treating biological surfaces to prevent coronavirus infection and spread. These compounds can also serve as viral disinfectants.
Career Highlights
Throughout his career, Robert Konrat has worked with reputable organizations such as Cebina GmbH and Universität Wien. His experience in these institutions has allowed him to advance his research and contribute to significant innovations in antiviral treatments.
Collaborations
Konrat has collaborated with notable colleagues, including Eszter Nagy and Gabor Nagy. Their joint efforts have further enhanced the research and development of antiviral solutions.
Conclusion
Robert Konrat's innovative work in antiviral treatments demonstrates his commitment to addressing pressing health challenges. His contributions are vital in the ongoing battle against viral infections, particularly in the context of the coronavirus pandemic.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile